Nara Daubeney and Piers Daubeney, CEO and Co-Founder, Phaim | Onyx Live | JPM 2026
Millions of T1DM patients worldwide are on lifelong insulin and constant monitoring. But what if we could switch off the immune attack causing the disease?
Daniel Green, CEO, eSpraye | JPM 2026
If the disease is in the lungs, why deliver the drugs everywhere else?
Fabian Gerlinghaus, CEO, Cellares | Onyx Live | JPM 2026
The platform built to cut CAR-T manufacturing costs by ~50% is about to power its first patient dosing.
Stefan Scherer, CEO, 3T Biosciences | JPM 2026
Many biotechs are trying to perfect T cell targeting - but how many have the backing of Sean Parker and Thiel Capital?
Nick Delmonico, CEO, Strados Labs | Onyx Live | JPM 2026
1 in 5 patients hospitalized with COPD are readmitted within 30 days of discharge - costing the US over $15 billion. But why?
Inside nChroma Bio’s push to deliver a functional cure for Hepatitis B
Epigenetic silencing is emerging as one of biotech’s boldest bets, and nChroma Bio is racing to prove it in the clinic. ‘Functional cures have been elusive, but epigenetic silencers are uniquely suited to the biological challenge for hepatitis B patients,’ Jeff Walsh says.
How is AI changing biotech diligence? | Treehill Partners Ep. 1 | Onyx Live | JPM 2026
The status quo is over.
How Genomenon finds order in 11 million scientific papers
Biology’s data problem isn’t scarcity, it’s structure. Genomenon is addressing it by converting millions of scientific papers into usable genomic intelligence. “If Google had gone to school to get a PhD in molecular biology, that's what Mastermind is,” says CEO Mike Klein.
The physics mindset behind one of biotech’s fastest-growing diagnostics companies
BillionToOne’s CEO, Dr. Oguzhan Atay, argues that “we are approaching biological problems from physics-based principles,” a mindset driving the company’s rapid growth, long-term focus, and pursuit of ultra-sensitive cancer and prenatal testing.
The first inning of a new research paradigm: Emulate, Inc. and the rise of organ-on-a-chip technology
As regulators, pharma, and researchers search for more predictive tools, Emulate, Inc’s CEO, Jim Corbett, argues that Organ-on-a-Chip technology is still early. “If this were a nine-inning baseball game, we’re in the first inning - but the direction is very clear.”
FDA approvals - December 2025
The winter batch of FDA approvals featured therapies that compress intervention into fewer doses, fewer visits, and fewer points of failure.
Lexicon’s next act: betting big on first-in-class cardiometabolic medicine
“We’re really on the precipice of moving the company into that next stage of maturity,” Dr. Mike Exton
“Speed is survival”: inside 4D Molecular Therapeutics’ bid to scale genetic medicine
Driven by the precision of viral biology, 4D Molecular Therapeutics is redefining gene therapy’s reach - scaling a once ultra-rare field into broad, sustainable markets.